Outside from the Ministry of Health.
he Ministry of Health This Friday published the medicines that achieved the approval of the Price Committee (Cipm) For general financing. At April, CIPM gave “OK” Five drugs, two of them orphans; In addition to expanding pediatrics for two others already approved above.
Los New accredited drugs Son: ObGESE (Vegrón), Balversa (Erditinib), Blincyt (Blincyto), Lampit (Niftymox) y icirvo (elafibranor).
The first of them, ObgemsaIt is a symptom of symptoms for adult patients with excessive bladder syndrome (VH). BallversaTreatment in unilateral therapy for adult patients with Uroothelia cancer (CU) that cannot be solved or metastatic carriers of the specified genetic changes FGFR3, which has already received at least one treatment line with PD-1 or PD-L1 inhibitors in the context of insecure or metastatic treatment.
Orphan Blincyto It was approved with these four indicators:
- The treatment of adults in the mono -therapy of LLA from the cells of cell B with negative vadelphia chromosome, positive CD19 in a complete or complete remission of the second and with the minimum remaining disease (EMR) is equal to or greater than 0.1 %.
- Treating patients with children between the ages of one month of age in unilateral treatment with BLA from the SAIs B with negative Philadelphia chromosome, positive CD19 and in the case of refraction or relapse after receiving at least two previous treatment or relapse after he received Alogenic transplantation from blood stem cells.
- Treating patients with children with 1 month of age in mono therapy with BLA from SAIs B with negative Philadelphia chromosome, CD19 is positive in the first high relapse as part of the monotheism treatment.
- Treatment of monotheism in unilateral treatment for adult patients with LLA from SAR B with Philadelphia Chromosome and positive diagnosis CD19.
For its part, Latted It is noteworthy that the treatment of Chagas (American Tribanosomic disease) caused by trarbanosoma in childhood patients from birth (newborn for its weight at least 2.5 kg) reaches children under the age of 18 years. As a treatment for Chagas disease in adult patients after individual evaluation (case case) for the relationship of benefits.
last, Iquevo It is approved as a treatment for the first bile bile inflammation (CBP) in conjunction with Ursodesoxicolic acid (AUDC) in adults who do not respond sufficiently to AUDC or as a single treatment in patients who do not tolerate AUDC.
Pediatric extensions
Likewise, it was agreed to finance the extension of the signal in childhood patients in medicines:
Creszma (Strizol), As a treatment in adults and child patients of 1 years of gaseous and hoop machine guns in patients who are not suitable for Emotetrisin B.
Y In the Evenakomab FezaA treatment for adult patients and children of 6 months of age with hfho hyperko (HFHO), as a supplement for diet and other Hypolipemian treatments to reduce cholesterol that is transferred by low-density sebaceous proteins (C-LDL).
The information published in the medical writing contains data, data and data from official institutions and health professionals. However, given any questions related to your health, consult the opposite health specialist.
